These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 21600941)
1. Cell-penetrating peptides can confer biological function: regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides. Brugnano JL; Chan BK; Seal BL; Panitch A J Control Release; 2011 Oct; 155(2):128-33. PubMed ID: 21600941 [TBL] [Abstract][Full Text] [Related]
2. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity. Schlapbach A; Feifel R; Hawtin S; Heng R; Koch G; Moebitz H; Revesz L; Scheufler C; Velcicky J; Waelchli R; Huppertz C Bioorg Med Chem Lett; 2008 Dec; 18(23):6142-6. PubMed ID: 18945615 [TBL] [Abstract][Full Text] [Related]
3. Thermosensitive nanoparticles with pH-triggered degradation and release of anti-inflammatory cell-penetrating peptides. Bartlett RL; Panitch A Biomacromolecules; 2012 Aug; 13(8):2578-84. PubMed ID: 22852804 [TBL] [Abstract][Full Text] [Related]
4. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting. Gurgis FM; Ziaziaris W; Munoz L Mol Pharmacol; 2014 Feb; 85(2):345-56. PubMed ID: 24296859 [TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II. Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669 [TBL] [Abstract][Full Text] [Related]
6. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2). Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547 [TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight MK2 inhibitors: a tough nut to crack! Schlapbach A; Huppertz C Future Med Chem; 2009 Oct; 1(7):1243-57. PubMed ID: 21426101 [TBL] [Abstract][Full Text] [Related]
8. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway. Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474 [TBL] [Abstract][Full Text] [Related]
9. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series. Oubrie A; Kaptein A; de Zwart E; Hoogenboom N; Goorden R; van de Kar B; van Hoek M; de Kimpe V; van der Heijden R; Borsboom J; Kazemier B; de Roos J; Scheffers M; Lommerse J; Schultz-Fademrecht C; Barf T Bioorg Med Chem Lett; 2012 Jan; 22(1):613-8. PubMed ID: 22119462 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-1-induced intracellular signaling pathways converge in the activation of mitogen-activated protein kinase and mitogen-activated protein kinase-activated protein kinase 2 and the subsequent phosphorylation of the 27-kilodalton heat shock protein in monocytic cells. Ahlers A; Belka C; Gaestel M; Lamping N; Sott C; Herrmann F; Brach MA Mol Pharmacol; 1994 Dec; 46(6):1077-83. PubMed ID: 7808427 [TBL] [Abstract][Full Text] [Related]
11. Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions. Ward BC; Kavalukas S; Brugnano J; Barbul A; Panitch A J Surg Res; 2011 Jul; 169(1):e27-36. PubMed ID: 21492875 [TBL] [Abstract][Full Text] [Related]
12. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800. Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052 [TBL] [Abstract][Full Text] [Related]
13. Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro. Hendriks BS; Seidl KM; Chabot JR BMC Syst Biol; 2010 Mar; 4():23. PubMed ID: 20230629 [TBL] [Abstract][Full Text] [Related]
14. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. Foey AD; Parry SL; Williams LM; Feldmann M; Foxwell BM; Brennan FM J Immunol; 1998 Jan; 160(2):920-8. PubMed ID: 9551930 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor. Lopes LB; Flynn C; Komalavilas P; Panitch A; Brophy CM; Seal BL Biochem Biophys Res Commun; 2009 May; 382(3):535-9. PubMed ID: 19289101 [TBL] [Abstract][Full Text] [Related]
16. Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dog. Morris DL; O'Neil SP; Devraj RV; Portanova JP; Gilles RW; Gross CJ; Curtiss SW; Komocsar WJ; Garner DS; Happa FA; Kraus LJ; Nikula KJ; Monahan JB; Selness SR; Galluppi GR; Shevlin KM; Kramer JA; Walker JK; Messing DM; Anderson DR; Mourey RJ; Whiteley LO; Daniels JS; Yang JZ; Rowlands PC; Alden CL; Davis JW; Sagartz JE Toxicol Pathol; 2010 Jun; 38(4):606-18. PubMed ID: 20448081 [TBL] [Abstract][Full Text] [Related]
17. Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signal-integrating kinases. Kjellerup RB; Kragballe K; Iversen L; Johansen C Exp Dermatol; 2008 Jun; 17(6):498-504. PubMed ID: 18081851 [TBL] [Abstract][Full Text] [Related]
18. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Hitti E; Iakovleva T; Brook M; Deppenmeier S; Gruber AD; Radzioch D; Clark AR; Blackshear PJ; Kotlyarov A; Gaestel M Mol Cell Biol; 2006 Mar; 26(6):2399-407. PubMed ID: 16508014 [TBL] [Abstract][Full Text] [Related]
19. Bacterial lipoprotein-induced self-tolerance and cross-tolerance to LPS are associated with reduced IRAK-1 expression and MyD88-IRAK complex formation. Li CH; Wang JH; Redmond HP J Leukoc Biol; 2006 Apr; 79(4):867-75. PubMed ID: 16461741 [TBL] [Abstract][Full Text] [Related]
20. Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas as potent inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). Lin S; Lombardo M; Malkani S; Hale JJ; Mills SG; Chapman K; Thompson JE; Zhang WX; Wang R; Cubbon RM; O'Neill EA; Luell S; Carballo-Jane E; Yang L Bioorg Med Chem Lett; 2009 Jun; 19(12):3238-42. PubMed ID: 19423344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]